Ayadi Lobna, Khabir Abdelmajid, Amouri Habib, Karray Sondes, Dammak Abdallah, Guermazi Mohamed, Boudawara Tahya
Department of Pathology, Habib Bourguiba University Hospital, Sfax, Tunisia.
World J Surg Oncol. 2008 Oct 22;6:112. doi: 10.1186/1477-7819-6-112.
Breast carcinoma is a disease with a tremendous heterogeneity in its clinical behavior. Newer prognostic factors and predictors of response to therapy are needed. The aim of this study was to evaluate the expression of HER-2, estrogen receptor (ER) and progesterone receptors (PR) in breast carcinoma and to compare it with other prognostic parameters such as histological type and grade, tumor size, patients' age, and lymph node metastases.
This is a retrospective study conducted in the department of pathology at Sfax University Hospital. Confirmed 155 Cases of breast carcinoma were reviewed in the period between January 2000 and December 2004. We used immunohistochemistry to evaluate the expression of HER-2, ER, and PR receptor and Chi-square and Fisher exact test to correlate immunohistochemical findings with prognostic parameters for breast carcinoma such as patients' age, tumor size, histological type, histological grade and lymph node status.
The mean age of patients was 51.5 years, ranging from 22 to 89 years. 80 (51.6%) of the patients were below 50 years. The percentage of expression of HER-2, ER and PR was 26, 59.4, and 52.3%, respectively. HER-2 was over-expressed (3+) in 18.1% of the cases, was inversely related to ER expression (p = 0.00) and to PR expression (p = 0.048). This over-expression was also associated with a high tumor grade with marginal significance (p = 0.072). A negative correlation was noted between ER and PR expression and SBR grade (p = 0.000) and ER and age (p = 0.002).
HER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting female patients. This group presents apparently an aggressive form of breast carcinoma with high histological grade and negative ER.
乳腺癌是一种临床行为具有极大异质性的疾病。需要更新的预后因素及治疗反应预测指标。本研究旨在评估乳腺癌中HER-2、雌激素受体(ER)和孕激素受体(PR)的表达,并将其与其他预后参数如组织学类型和分级、肿瘤大小、患者年龄及淋巴结转移情况进行比较。
这是一项在斯法克斯大学医院病理科开展的回顾性研究。对2000年1月至2004年12月期间确诊的155例乳腺癌病例进行了回顾。我们采用免疫组织化学方法评估HER-2、ER和PR受体的表达,并使用卡方检验和Fisher精确检验将免疫组织化学结果与乳腺癌的预后参数如患者年龄、肿瘤大小、组织学类型、组织学分级及淋巴结状态进行关联分析。
患者的平均年龄为51.5岁,年龄范围为22至89岁。80例(51.6%)患者年龄小于50岁。HER-2、ER和PR的表达百分比分别为26%、59.4%和52.3%。HER-2在18.1%的病例中过度表达(3+),与ER表达呈负相关(p = 0.00),与PR表达呈负相关(p = 0.048)。这种过度表达还与高肿瘤分级相关,具有边缘显著性(p = 0.072)。ER和PR表达与SBR分级之间呈负相关(p = 0.000),ER与年龄之间呈负相关(p = 0.002)。
在突尼斯女性乳腺癌患者中,18.1%观察到HER-2过度表达。这组患者显然呈现出一种具有高组织学分级和ER阴性的侵袭性乳腺癌形式。